197 related articles for article (PubMed ID: 9300576)
1. Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin.
Bennis S; Faure P; Chapey C; Hu YP; Fourche J; El Yamani J; Robert J
Anticancer Drugs; 1997 Jul; 8(6):610-7. PubMed ID: 9300576
[TBL] [Abstract][Full Text] [Related]
2. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
Mankhetkorn S; Garnier-Suillerot A
Eur J Pharmacol; 1998 Feb; 343(2-3):313-21. PubMed ID: 9570481
[TBL] [Abstract][Full Text] [Related]
3. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.
Consoli U; Priebe W; Ling YH; Mahadevia R; Griffin M; Zhao S; Perez-Soler R; Andreeff M
Blood; 1996 Jul; 88(2):633-44. PubMed ID: 8695811
[TBL] [Abstract][Full Text] [Related]
4. Pirarubicin nuclear uptake does not correlate with its induced cell death effect during reversal of multidrug resistance by quinine in human K562 and CEM leukemic cells.
Morjani H; Belhoussine R; Lahlil R; Manfait M
Eur J Haematol; 1998 Oct; 61(4):240-9. PubMed ID: 9820630
[TBL] [Abstract][Full Text] [Related]
5. [Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry].
Belhoussine R; Morjani H; Manfait M
Bull Cancer; 1997 Apr; 84(4):343-9. PubMed ID: 9238156
[TBL] [Abstract][Full Text] [Related]
6. Partial inhibition of the P-glycoprotein-mediated transport of anthracyclines in viable resistant K562 cells after irradiation in the presence of a verapamil analogue.
Mankhetkorn S; Teodori E; Garnier-Suillerot A
Chem Biol Interact; 1999 Jul; 121(2):125-40. PubMed ID: 10418960
[TBL] [Abstract][Full Text] [Related]
7. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells.
Siegsmund MJ; Stendler A; Kreukler C; Köhrmann KU; Alken P
Eur Urol; 1997; 31(3):365-70. PubMed ID: 9129933
[TBL] [Abstract][Full Text] [Related]
8. Development of drug resistance is reduced with idarubicin relative to other anthracyclines.
Hargrave RM; Davey MW; Davey RA; Kidman AD
Anticancer Drugs; 1995 Jun; 6(3):432-7. PubMed ID: 7670142
[TBL] [Abstract][Full Text] [Related]
9. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids.
Pereira E; Tarasiuk J; Garnier-Suillerot A
Chem Biol Interact; 1998 Jul; 114(1-2):61-76. PubMed ID: 9744556
[TBL] [Abstract][Full Text] [Related]
10. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
Mülder HS; Dekker H; Pinedo HM; Lankelma J
Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
[TBL] [Abstract][Full Text] [Related]
11. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.
Lehne G; De Angelis P; Clausen OP; Rugstad HE
Br J Cancer; 1996 Dec; 74(11):1719-29. PubMed ID: 8956784
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline subcellular distribution in human leukemic cells by microspectrofluorometry: factors contributing to drug-induced cell death and reversal of multidrug resistance.
Morjani H; Millot JM; Belhoussine R; Sebille S; Manfait M
Leukemia; 1997 Jul; 11(7):1170-9. PubMed ID: 9205008
[TBL] [Abstract][Full Text] [Related]
14. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
15. D-verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin.
Damiani D; Michieli M; Michelutti A; Melli C; Cerno M; Baccarani M
Anticancer Drugs; 1993 Apr; 4(2):173-80. PubMed ID: 8098233
[TBL] [Abstract][Full Text] [Related]
16. In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells.
Wang Y; Eksborg S; Lewensohn R; Lindberg A; Liliemark E
Anticancer Drugs; 1999 Nov; 10(10):921-8. PubMed ID: 10630360
[TBL] [Abstract][Full Text] [Related]
17. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives.
Michieli M; Michelutti A; Damiani D; Pipan C; Raspadori D; Lauria F; Baccarani M
Leuk Lymphoma; 1993 Feb; 9(3):255-64. PubMed ID: 8097129
[TBL] [Abstract][Full Text] [Related]
18. Evidence for reversal of multidrug resistance by quinine in LR73 cells without alteration of nuclear pirarubicin uptake and down-regulation of mdr1 gene expression.
Belhoussine R; Morjani H; Lahlil R; Manfait M
Int J Cancer; 1997 Nov; 73(4):600-6. PubMed ID: 9389578
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
Bogush T; Robert J
Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line.
Bennis S; Ichas F; Robert J
Int J Cancer; 1995 Jul; 62(3):283-90. PubMed ID: 7628869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]